The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted ADvantage Therapeutics’ immunotherapy AD04 an Innovation Passport for the treatment of Alzheimer’s disease.  

The designation, under the regulator’s Innovative Licensing and Access Pathway (ILAP), will fast-track a potential route to market for AD04 by providing collaborative opportunities with UK institutes like the National Institute for Health and Care Excellence (Nice).

The Miami, US-based company will carry out a Phase IIb trial that will investigate hippocampal volume changes and assess multiple AD and cognition scales over 12 months in patients with mild Alzheimer’s disease.  

The difficulty in finding a treatment for Alzheimer’s disease has plagued the drug industry for decades. A recent wave of monoclonal antibodies, including the FDA-approved Eisai/Biogen’s Leqembi (lecanemab), is expected to shake up the space. Advantage Therapeutics claims AD04’s immunomodulatory approach may reduce AD pathology, which is a different mechanism from other drugs designed towards a specific target in AD pathologies like amyloid beta or tau.

“We are delighted that MHRA has recognized the potential of AD04 at [the] same time we are launching our confirmatory trial,” said Jeffrey Madden, chief executive officer of Advantage in an April 5 press release.

“We believe our novel immunotherapy for Alzheimer’s has a low manufacturing cost, simple storage, subcutaneous administration, and believe that forthcoming clinical studies will confirm safety, efficacy and tolerability. If proven and approved, the rapid introduction of AD04 into the U.K. health system may support accelerated clinical adoption in other worldwide healthcare systems.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.